Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025
Spero Therapeutics (NASDAQ: SPRO), a clinical-stage biopharmaceutical company specializing in rare diseases and multi-drug resistant bacterial infections treatments, will release its first quarter 2025 financial results after market close on Tuesday, May 13, 2025. The company will also provide a business update but has stated it will not host a conference call for this earnings announcement.
Spero Therapeutics (NASDAQ: SPRO), un'azienda biofarmaceutica in fase clinica specializzata in malattie rare e trattamenti per infezioni batteriche multi-resistenti, pubblicherà i suoi risultati finanziari del primo trimestre 2025 dopo la chiusura del mercato di martedì 13 maggio 2025. La società fornirà anche un aggiornamento aziendale, ma ha dichiarato che non terrà una conference call per questo annuncio dei risultati.
Spero Therapeutics (NASDAQ: SPRO), una empresa biofarmacéutica en etapa clínica especializada en enfermedades raras y tratamientos para infecciones bacterianas multirresistentes, publicará sus resultados financieros del primer trimestre de 2025 después del cierre del mercado el martes 13 de mayo de 2025. La compañía también proporcionará una actualización comercial, pero ha indicado que no realizará una llamada de conferencia para este anuncio de ganancias.
Spero Therapeutics (NASDAQ: SPRO)는 희귀 질환 및 다제내성 세균 감염 치료에 특화된 임상 단계의 생명공학 회사로, 2025년 1분기 재무 결과를 2025년 5월 13일 화요일 시장 마감 후 발표할 예정입니다. 회사는 사업 업데이트도 제공할 예정이나, 이번 실적 발표를 위한 컨퍼런스 콜은 진행하지 않을 것이라고 밝혔습니다.
Spero Therapeutics (NASDAQ : SPRO), une entreprise biopharmaceutique en phase clinique spécialisée dans les maladies rares et les traitements des infections bactériennes multirésistantes, publiera ses résultats financiers du premier trimestre 2025 après la clôture du marché le mardi 13 mai 2025. La société fournira également une mise à jour commerciale, mais a indiqué qu’elle n’organiserait pas de conférence téléphonique pour cette annonce de résultats.
Spero Therapeutics (NASDAQ: SPRO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf seltene Krankheiten und Behandlungen gegen multiresistente bakterielle Infektionen spezialisiert hat, wird seine Finanzergebnisse für das erste Quartal 2025 nach Börsenschluss am Dienstag, den 13. Mai 2025 veröffentlichen. Das Unternehmen wird auch ein Geschäft-Update geben, hat jedoch angekündigt, keine Telefonkonferenz für diese Gewinnbekanntgabe abzuhalten.
- None.
- None.
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2025 financial results and provide a business update on Tuesday, May 13, after the market close. The Company does not intend to host a conference call.
About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infections with high unmet need. For more information, visit www.sperotherapeutics.com
Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotherapeutics.com
Media Inquiries:
media@sperotherapeutics.com
FAQ
When will Spero Therapeutics (SPRO) release Q1 2025 earnings?
Will Spero Therapeutics hold an earnings call for Q1 2025 results?
What is Spero Therapeutics' (SPRO) main business focus?
What stock exchange is Spero Therapeutics listed on?
